glp 1 agonist history Another milestone in the evolution of GLP-1-based diabetes therapies It's important to study the
Description
This study showed that the risk of recurrent pancreatitis in a cohort of patients taking GLP-1 receptor agonists (10%) was likely no greater than what is observed in the general population and that more than half of the episodes of recurrent pancreatitis were attributable to causes other than GLP-1 receptor agonist therapy
58.United State Food and Drug Administration
Liu H, Zhan YL, Luo GJ, Zou LL, Li Y, Lu HY
About half of heart failure patients have this type, according to the American College of Cardiology
GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell
le Roux, Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
